What is IN8bio?
Founded in 2016 and headquartered in New York, IN8bio is dedicated to pioneering next-generation cellular therapies aimed at combating cancer. The company's innovative pipeline focuses on developing both allogeneic and autologous gamma-delta T cell therapies, positioning it at the forefront of advanced oncology treatments. This focus on novel therapeutic modalities highlights IN8bio's commitment to addressing unmet needs in cancer care.
How much funding has IN8bio raised?
IN8bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in IN8bio
PPP
Public-Private Partnership
What's next for IN8bio?
The substantial late-stage funding IN8bio has attracted signals a critical phase of scaling and market penetration. This capital infusion is expected to accelerate the development and potential commercialization of its gamma-delta T cell therapies. Strategic partnerships and further clinical validation will likely be key priorities as the company navigates its path toward becoming a leader in the cellular therapy sector.
See full IN8bio company page